Introduction
============

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by chronic joint inflammation and variable degrees of bone and cartilage erosion. The etiology of RA is related to genetic and environmental factors, such as viral infection, hormone levels and mental state. The morbidity of RA in women is 2-3 times higher than in men, but the underlying mechanism remains unknown [@B1], [@B2]. Recent evidence suggests that fibroblast-like synoviocytes (FLSs) are implicated in the pathogenesis of RA. The apoptosis and proliferation of FLSs play important role in the occurrence and development of RA, but the detailed mechanism remains to be explored [@B3].

Peptidylarginine deiminase (PAD) converts peptidylarginine into citrulline in the presence of Ca^2+^, in a process known as citrullination. The PAD family includes five distinct isozymes, PADI1, PADI2, PADI3, PADI4 and PADI6. Among them, PADI4 is expressed in a variety of blood cells [@B4], [@B5]. However, overexpression of PADI4 has been observed in synovial organization and peripheral blood mononuclear cells (PBMCs) of RA patients [@B6], [@B7]. Moreover, PADI4 expression was specifically induced by collagen in the inflammation period in RA rat model [@B8]. These results suggest that abnormally high expression of PADI4 is a key factor in the development of RA.

Citrullination of the proteins leads to significant changes in their biological activity, such as the regulation of cell proliferation and apoptosis [@B9], [@B10]. Histones H3 and H4 are the first substrate proteins identified which could be citrullinated by PADI4 at different Arginine (Arg, R) residues. In particular, PADI4 increases the citrullination at arginine 3 residue of histone H4 (H4R3cit) and arginine 17 residue of histone H3 (H3R17cit) [@B11]. Recently, we demonstrated that non-histone protein vimentin is a direct substrate citrullinated by PADI4. The citrullinated vimentin effectively promotes the proliferation of FLSs isolated from RA patients [@B12]. Given the fact that the major citrullination substrate of PADI4 is histone, we speculated that PADI4 might play a role in RA by regulating the citrullination on histone which modulates the transcription of key genes during the development of RA.

In the present study, we employed both gain and loss of function approaches to illustrate the anti-apoptosis function of PADI4 in RA-FLSs. PADI4 negatively regulated the apoptosis of RA-FLSs via inhibiting the expression of p53 and its target protein p21. Furthermore, chromatin immunoprecipitation (ChIP) assays indicated a decrease in histone H3 arginine citrullination and an increase in histone H3 arginine methylation at H3R17 on the p21 promoter.

Materials and methods
=====================

Patients
--------

Primary synovial tissues were obtained from two female RA patients who underwent knee arthroscopic or replacement surgery (Table [1](#T1){ref-type="table"}). The tissue samples were immediately suspended in 1640 medium and processed within 4 h for FLSs culture and histological and immunohistochemical analysis. The clinical diagnosis of RA was based on American College of Rheumatology (ACR) criteria. All patients were asked to consent before enrolling into this medical research. The Ethics Committee of Shanghai East Hospital approved the study protocol.

Isolation and culture of FLSs
-----------------------------

Synovial tissues were minced into pieces of 2-3 mm in size and spread on the bottom of cell culture flasks in 1640 medium at 37°C for 6 h. Next, the tissues were incubated with complete 1640 medium, supplemented with 10% fetal calf serum in a humidified atmosphere containing 5% CO~2~. The medium was changed every 3-5 days and non-adherent tissue pieces were carefully removed. FLSs were grown further over 4-6 passages. To characterize the cytological phenotype of synovial cultures, the third passage cells were stained with mouse mAb against human CD14 and CD90 (eBioscience, San Diego, CA, USA) and analyzed by flow cytometry.

RNA Interference and Plasmids Construction
------------------------------------------

Two small interfering RNAs (siRNAs) against human PADI4 (si-944: 5′-CAGGAGGTGTACGCGTGCAGTATTT-3′; si-1225: 5′-GGGTATCAGTGGACTGGACTCCTTT-3′) and negative control siRNA (si-NC: 5′-TTCTCCGAACGTGTCACGT-3′) were synthesized by Genepharma (Shanghai, China). Full-length cDNA encoding human PADI4 was amplified by using primers forward: GCTGAATTCATGGCCCAGGGGACATTGATC and reverse: AGTGGATCCGGGCACCATGTTCCACCA. pcDNA3.1-PAID4 was constructed by inserting the PADI4 PCR product. FLSs were transfected with siRNAs by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) at 30% confluency, while transfected with plasmids by using Lipo-LTX (Invitrogen, Carlsbad, CA, USA) at 80% confluency.

Quantitative Real-time-PCR (qRT-PCR)
------------------------------------

Total RNA was extracted from FLSs by using TRIzol (Invitrogen, Carlsbad, CA, USA). The reverse transcription was performed by using a first strand cDNA synthesis kit (Takara, Dalian, China) according to the manufacturer\'s instructions. Real-time PCR was performed using Premix Ex Taq SYBR Green PCR (Takara, Dalian, China) according to the manufacturer\'s instructions on an ABI PRISM 7300 (Applied Biosystems, Foster City, CA, USA). The sequences of the primers were as follows: PADI4 forward: 5\'-CACAGCTCTGGTTGGCTTCA-3\', reverse: 5\'-CTGCACGTCCTTCAGCATCA-3\'; p21 forward: 5\'-AGAACCCATGCGGCAGCAAG-3\', reverse: 5\'-TGGATGCAGCCCGCCATTAG-3\'; p53 forward: 5\'-GTGAGGGATGTTTGGGAGATG-3\', reverse: 5\'-CCTGGTTAGTACGGTGAAGTG-3\'; β-actin forward: 5\'-TGACTTCAACAGCGACACCCA-3\', reverse: 5\'-CACCCTGTTGCTGTAGCCAAA-3\'. β-actin was used as internal control.

Western blot analysis
---------------------

Whole cell lysates were prepared from about 2×10^5^ cells by homogenization in lysis buffer and subsequent centrifugation at 14,000 rpm for 15 min. The protein concentration in the supernatant was determined using the Bradford method (Bio-Rad, Hercules, CA, USA). Protein samples were separated on 10% SDS-PAGE and then transferred onto nitrocellulose membranes (Amersham Pharmacia Biotech, Uppsala, Sweden). The membranes were blocked in 5% skimmed milk, and incubated overnight with primary antibodies anti-Flag (Sigma, \#F3165), anti-Beta-actin (Santa Cruz, \#sc-47778), anti-p53 (Abcam, \# ab26), anti-PADI4 (Abcam, \# ab38772), anti-p21 (Abcam, \# ab7960), anti-citrullinated histone H3 (Abcam, \# ab5103), anti-Arg-dimethyl histone H3 (Abcam, \# ab8284) or anti-monomethyl histone H4 (Abcam, \# ab17339), then washed 3 times with TBST every 5 min. The membrane was incubated with horseradish peroxidase-conjugated secondary antibody for one hour, and then washed with TBST 3 times every 10 min. The immunoreactive bands were visualized with SuperSignals west Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL, USA).

Flow cytometry analysis of apoptosis
------------------------------------

Adriamycin (ADR) was administered to FLSs at a dose of 1 μg/ml for 24 h. For flow cytometry analysis, the FLSs were trypsinized and collected for the detection of apoptosis by using an Annexin V-FITC Apoptosis Detection Kit (eBioscience, San Diego, CA, USA). Briefly, FLSs were washed twice with cold PBS and suspended in 500 μl binding buffer (10 mM HEPES-NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl~2~) at a concentration of 1×10^6^ cells/ml. After the addition of 5 μl Annexin V-FITC solution and PI (1 μg/ ml), the cells were incubated for 15 min at room temperature and then analyzed by flow cytometer (Beckman Coulter, Fullerton, CA, USA).

Chromatin Immunoprecipitation analysis
--------------------------------------

Chromatin immunoprecipitation (ChIP) assay was performed by using an EZ-ChIP Chromatin Immunoprecipitation Kit (Millipore, MA, USA, \#17-371) according to the manufacturer\'s instructions. Sonicated chromatin was incubated at 4°C overnight with antibodies against PADI4, CitH3 (citrullination of H3R2, R8 and R17), and H3R17me2, respectively. The bound DNA fragments were analyzed by PCR using HotStart Taq enzyme (Takara, Dalian, China). The primers designed to detect the -8 promoter region of p21 (forward: 5′-TATATCAGGGCCGCGCTG-3′ and reverse: 5′-GGCTCCACAAGGAACTGACTTC-3′) and the primers to detect GAPDH promoter region (forward: 5′-CAATTCCCCATCTCAGTCGT-3′ and reverse: 5′-TAGTAGCCGGGCCCTACTTT-3′) were synthesized by Invitrogen (Carlsbad, CA, USA). GAPDH was used as negative control [@B13].

Immunohistochemistry staining (IHC)
-----------------------------------

Synovial tissues were dissected and processed following standard IHC protocols. In brief, the tissue was fixed with 4% paraformaldehyde in phosphate buffered saline, dehydrated and embedded in paraffin wax. The sections were deparaffinized, rehydrated and incubated with PADI4 or p21 antibody (Abcam) followed with incubation with secondary rabbit antibody. The staining was performed following the manual of Vectastain ABC kit (Vector Laboratories). Stain images were captured using a Leica DM 4M light microscope (Leica).

Statistical analysis
--------------------

Data were expressed as mean ± standard deviation (SD) and analyzed by using a SPSS16.0 program package (SPSS Inc., Chicago, IL, USA). Comparison was performed by an independent t-test. *P* \<0.05 was considered statistically significant.

Results
=======

Abundant PADI4 expression in RA is associated with less apoptosis
-----------------------------------------------------------------

To explore the expression pattern of PADI4 in osteoarthritis (OA) and RA, we performed immunohistochemistry staining and quantitative RT-PCR on synovial tissues from RA and OA patients. PADI4 staining signal and mRNA level are both dramatically higher in RA compared to OA (Fig. [1](#F1){ref-type="fig"}A&B). In addition, we observed a negative correlation between PADI4 and p21 staining in synovial tissues from RA and OA patients (Table [2](#T2){ref-type="table"}).

Furthermore, we treated RA and OA FLS cells with a well-known apoptosis-inducing agent Adriamycin (ADR), and measured the apoptotic cells by Annexin V/PI staining. Flow cytometry analysis showed that the percentage of apoptotic cells increased about 10-fold in RA-FLSs and almost 20-fold in OA-FLSs after ADR treatment (Fig. [1](#F1){ref-type="fig"}C). These data suggest that abundant expression of PADI4 in FLS cells is negatively associated with the induction of apoptosis.

PADI4 depletion promotes the apoptosis of RA-FLSs
-------------------------------------------------

To confirm the anti-apoptosis function of PADI4, we depleted PADI4 expression in RA-FLSs by siRNAs. Western blot and RT-PCR analysis confirmed that two PADI4 specific siRNAs (si-944 and si-1225) both significantly decreased PADI4 expression at protein and mRNA levels in RA-FLSs derived from two RA patients (Fig. [2](#F2){ref-type="fig"}A). Next, we performed flow cytometry analysis and found that the ratio of apoptotic cells was significantly higher in PADI4 depleted RA-FLSs compared to RA-FLSs transfected with control siRNA (Fig. [2](#F2){ref-type="fig"}B).

To verify that PADI4 protects RA-FLSs from apoptosis, we detected the expression of two key pro-apoptotic proteins p53 and p21 in PADI4 depleted RA-FLSs. Western blot analysis showed that protein levels of p53 and p21 increased in RA-FLSs treated with PADI4 siRNAs (Fig. [2](#F2){ref-type="fig"}A). Furthermore, we found that PADI4 level was decreased in ADR treated RA-FLSs, while p53 and p21 levels were consistently increased (Fig. [2](#F2){ref-type="fig"}C).

PADI4 rescues the RA-FLSs from apoptosis through inactivation of p21 and p53
----------------------------------------------------------------------------

Next, we generated PADI4 overexpression plasmid that successfully achieve a strong PADI4 expression in RA-FLSs (Fig. [3](#F3){ref-type="fig"}A). PADI4 overexpression in RA-FLSs significantly decreased the ratio of apoptotic cells (Fig. [3](#F3){ref-type="fig"}D). Similarly, ADR induced apoptosis in RA-FLSs was reversed after ectopic expression of PADI4 (Fig. [3](#F3){ref-type="fig"}E).

To explore the involvement of p21 and p53 in PADI4 mediated apoptosis inhibition, we compared the expression of p53 and p21 in ADR treated RA-FLSs with or without PADI4 overexpression. We found that PADI4 levels increased while p21 and p53 levels decreased in PADI4 overexpressing cells (Fig. [3](#F3){ref-type="fig"}B and 3C). Collectively, these results suggest that PADI4 inhibits the apoptosis of RA-FLSs through the inhibition of p21 and p53 transcription.

PADI4 reverses global H3 modification in RA-FLSs
------------------------------------------------

Given that PADI4 citrullinates histone H3 and H4, we further hypothesized that PADI4 may inhibit p21 transcription through an epigenetic mechanism. We found that PADI4 depletion led to global repression of CitH3 (Citrullinated H3R2 + R8 + R17) and global deposition of H3R17me2 in whole cell lysate of RA-FLSs (Fig. [4](#F4){ref-type="fig"}A). Interestingly, we detected decreased CitH3 and increased H3R17me2 in ADR-treated RA-FLSs (Fig. [4](#F4){ref-type="fig"}B). However, the increase of H3R17me2 and decrease of CitH3 were both significantly reversed by PADI4 (Fig. [4](#F4){ref-type="fig"}C). These results suggest that PADI4 globally reverses the key histone arginine modifications.

PADI4 enhances the recruitment of CitH3 to p21 promoter in RA-FLSs
------------------------------------------------------------------

To further determine the details of PADI4 inhibited p21 transcription, we conducted qChIP assays. We designed a pair of primers that specifically recognized the distal promoter region of p21 gene (Fig. [5](#F5){ref-type="fig"}A). Compared to IgG control, a decent PADI4 binding signal, a strong CitH3 binding signal and a weak H3R17me2 binding signal were detected on p21 promoter region (Fig. [5](#F5){ref-type="fig"}B). No PADI4 binding signal was detected with GAPDH promoter (data not shown).

Compared to non-treated RA-FLSs, we observed weaker CitH3 occupancy and stronger H3R17me2 occupancy on p21 promoter region in ADR treated RA-FLSs (Fig. [5](#F5){ref-type="fig"}C). PADI4 occupancy on p21 promoter was not significantly affected after ADR treatment.

Discussion
==========

Protein methylation, especially the methylation of lysine, has been regarded as one of the key epigenetic mechanisms that regulate gene expression. However, protein citrullination emerges as a new form of protein post-translational modification that plays a unique role in epigenetic gene regulation [@B14]-[@B17]. PADI4 is a member of the PADI family that regulates protein citrullination. PADI4 was found to be highly expressed in RA synovial tissue but the biological function of PADI4 in RA development, especially in the apoptosis, remains controversial. Soem et al. showed that high expression of PADI4 induced cell apoptosis [@B18], [@B19], while others showed that down-regulation of PADI4 led to retroaction [@B20], [@B21]. Our recent study reported that PADI4 was highly activated in RA-FLS by stimulating with citrullinated vimentin [@B12]. In this study we provide further evidence that PADI4 protects RA-FLSs from apoptosis through suppressing p21 transcription via an epigenetic mechanism.

During RA development, the in vivo citrullinated proteins accumulate as a result of high expression of PADI4 [@B22], [@B23]. In addition, the locus of PADI4 gene SNP is highly correlated with RA susceptibility [@B6], [@B24], [@B25]. It was reported that the positive rate of anti-PADI4 antibody and its titer in RA patients were higher than in patients with other rheumatic diseases or healthy people, indicating that PADI4 protein is likely to participate in RA autoimmune reaction [@B26], [@B27]. However, the detailed mechanism by which PADI4 regulates RA development remains elusive.

In the present study, we showed for the first time that PADI4 inhibits cell apoptosis of RA-FLSs, and the underlying mechanism involves the histone H3 modifications altered by PADI4. Based on our findings, we proposed a working model to explain the contribution of PADI4 to RA development. High level of PADI4 recruits repressive histone mark CitH3, including H3R17cit, to p21 promoter, which competitively removes the active histone mark (H3R17me2) on the same residue (Fig. [6](#F6){ref-type="fig"}A). As a result, p21 transcription was impeded and the cells were protected from apoptosis, which eventually leads to the occurrence of RA. On the other hand, when PADI4 is down-regulated, reduced CitH3 and enhanced H3R17me2 activate p21 transcription. Consequently, the apoptosis of RA-FLSs is promoted and RA development is inhibited (Fig. [6](#F6){ref-type="fig"}B).

In addition, we found that PADI4 inhibited p53 expression in RA-FLSs. The downregulation of p53 may also explain the anti-apoptotic role of PADI4 in RA-FLSs. p21 is partly involved in the regulation of apoptosis by p53 [@B28], [@B29]. Moreover, several studies suggest that the function of p21 is dependent on p53 during the regulation of cell apoptosis by PADI4 [@B12], [@B20]. Intriguingly, PADI4 is also expressed at a high level in various types of adenocarcinomas, and one of the target genes of PADI4 is p53 [@B30], [@B31]. Further studies are needed to elucidate the mechanism by which PADI4 regulates p53 expression in RA-FLSs and investigate the role of p53 in the apoptotic regulation mediated by PADI4.

PADI4 catalyzes the citrullination of all proteins that contain arginine residues, such as H3, H4, vimentin, and fibronectin; and further catalytic substrates of PADI4 have been identified [@B17], [@B32]-[@B34]. Our recent studies reported that citrullinated vimentin and citrullinated fibronectin elevated PADI4 expression and promoted the proliferation of RA-FLSs [@B11], [@B12]. In this study we demonstrated that histone arginine citrullination in p21 promoter, as a poorly understood histone modification, could crosstalk with histone arginine methylation, which is one of the best-characterized modification that regulates gene transcription. More importantly, our data showed that this crosstalk plays a major role in the regulation of the apoptosis in RA-FLSs. Future studies are need to investigate how to interrupt PADI4 mediated citrullinations on histone proteins or other non-histone proteins as a potential therapy for RA. Additionally, our findings provide a clue for potential targeted therapeutic approaches to reverse the inflammation development of RA. One possibility is directly targeting histone arginine citrullination in p21 promoter for RA therapy. Another strategy is to develop small molecule inhibitors of PADI4. In vivo studies using animal RA model will be necessary to evaluate these approaches.

Conclusions
===========

For the first time we showed that PADI4 contributes to the pathogenesis of RA by inhibiting the apoptosis of FLSs. Down-regulation of PADI4 could increase the apoptosis of RA-FLSs, while up-regulation of PADI4 could decrease the apoptosis of RA-FLSs. Mechanistically, PADI4 disrupts histone H3 arginine modifications and suppresses p21 transcription. Our study provides new insight into the anti-apoptotic role of PADI4 in RA development and illuminate the epigenetic mechanism.
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![**PADI4 is highly expressed and inhibited the apoptosis of RA-FLSs.**(A) Immunohistochemistry staining of PADI4 in arthritic synovial tissues from RA and OA patients. Original magnification: x200. Images represent PADI4 and p21 antibodies staining, IgG control staining (Negative) and HE staining. (B) Quantitative RT-PCR analysis of PADI4 mRNA level in RA and OA FLSs. Data are presented after normalization by GAPDH. (C) Left: flow cytometry analysis of apoptotic RA and OA FLSs after ADR treatment (Upper left, untreated OA; Upper right, ADR treated OA; Lower left, untreated RA; Lower right, ADR treated RA). Right: quantification of apoptotic cells. \*, P\<0.05, \*\* P\<0.01.](ijbsv13p0358g001){#F1}

![**Knockdown of PADI4 promotes the apoptosis and increases the expression of p53 and p21 in RA-FLSs.** (A) RA-FLSs were transfected with siRNAs and the levels of p21 and p53 were evaluated by Western blot analysis (left) and qRT-PCR (right). (B) Flow cytometry analysis of apoptotic RA-FLSs after PADI4 knockdown for 72 h. (C) Western blot and qRT-PCR analyses of PADI4, p53 and p21 in RA-FLSs (R1 and R2) after treatment with ADR (1 μg/ml) for 24 h. \*, P\<0.05, \*\* P\<0.01.](ijbsv13p0358g002){#F2}

![**Ectopic expression of PADI4 inhibits the apoptosis and decreases p53 and p21 expression in RA-FLSs.** (A) RA-FLSs were transfected with overexpression plasmids and PAID4 protein was evaluated by Western blot analysis. (B & C) RA-FLSs were transfected with PADI4 overexpression plasmid and 24 h later treated with ADR. mRNA and protein levels of PADI4, p53 and p21 were measured by qRT-PCR (B) and Western blot analysis (C). (D & E) Flow cytometry analysis of apoptotic RA-FLSs after PADI4 overexpression alone (D) and in combination with ADR treatment (E). \*P\<0.05, \*\*P\<0.01.](ijbsv13p0358g003){#F3}

![**PADI4 modulates the citrullination/methylation of histone H3 in RA-FLSs.**(A) Western blot analysis of the levels of CitH3 (citrullination of H3R2, R8 and R17), H3R17me2, H4R3me and total histone H3 in RA-FLSs after transfection with PADI4 siRNAs. (B) Western blot analysis of the levels of CitH3, H3R17me2 and total histone H3 in RA-FLSs with ADR treatment. (C) Western blot analysis of the levels of CitH3, H3R17me2 and total histone H3 in PADI4 overexpressing RA-FLSs after ADR treatment.](ijbsv13p0358g004){#F4}

![**Recruitment of PADI4 and H3 to p21 promoter during apoptosis of RA-FLSs.** (A) Schematic diagram of the primer l location on p21 distal promoter region. (B) ChIP assays to examine histone H3R17me2, PADI4 and CitH3 binding signals on the p21 promoter. (C) ChIP assays to examine histone H3R17me, PADI4 and CitH3 binding signals on the p21 promoter in RA-FLS with ADR treatment.](ijbsv13p0358g005){#F5}

![**Model of the repressive role of PADI4 in p21 transcription.**PADI4 suppresses p21 transcription through the deposition of repressive mark CitH3 (for example, H3R17cit) and inhibition of the active mark H3R17me2 on p21 promoter region (A). ADR induced PDK4 down-regulation or siRNAs mediated PADI4 depletion promotes p21 transcription (B). H3R17cit: repressive histone H3R17 citrullination; H3R17me2: active histone H3R17 di-methylation.](ijbsv13p0358g006){#F6}

###### 

Clinical and serological characteristics of the patients

  ------------------------------------------------------------------------------------------------------------------------------
  Patient \#   Diagnosis   Gender   Age (year)   Disease duration\   Medications taken   ESR\     RF\       CRP\     Anti-CCP\
                                                 (year)                                  (mm/h)   (IU/mL)   (mg/L)   (IU/L)
  ------------ ----------- -------- ------------ ------------------- ------------------- -------- --------- -------- -----------
  1            RA          Female   65           11.5                MTX+Leflunomide     45       136.5     34.8     25.6

  2            RA          Male     59           8                   MTX+ SSZ            39       76.5      27.6     41.3
  ------------------------------------------------------------------------------------------------------------------------------

RA, rheumatoid arthritis; MTX, methotrexate; SSZ, sulfasalazine; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; CRP, C-reactive protein; anti-CCP, anti-cyclic citrullinated peptide antibody.

###### 

Negative correlation between PADI4 and p21 staining in synovial tissues from RA and OA patients.

  --------------------------------------------------------
  Staining   p21   Spearman\   p                        
                   r                                    
  ---------- ----- ----------- --- --- -------- ------- --
  PADI4      -/+   2           2   6   -0.518   0.003   

  ++         3     1           2                        

  +++        10    3           1                        

                                                        
  --------------------------------------------------------
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